why choose us

First received: November 24, 2022

Clinical Trial: A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Advanced Solid Tumors

Study Type: Interventional


Official Title: A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QL1604, a Humanized Anti-PD-1 Monoclonal Antibody, in Patients With Advanc

Brief Summary: This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection ?a humanized anti-PD-1 monoclonal antibody?in patients with advanced solid tumors.

Read more